GO:1902993 positive regulation of amyloid precursor protein catabolic process: APP Proteolysis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902993 describes any process that activates or increases the frequency, rate or extent of amyloid precursor protein (APP) catabolic process.
• APP catabolism is dominated by sequential proteolysis: α-, β-, and γ-secretase activities determine whether APP is cleared or generates amyloid-β (Aβ) peptides.
• Positive regulation of APP catabolism can be protective when it shifts processing toward non-amyloidogenic α-secretase cleavage, but pathological when it increases β-/γ-secretase-mediated Aβ production.
• IFITM3 is an innate immunity protein that modulates γ-secretase and influences APP catabolic flux, directly linking immune signaling to GO:1902993.
• Gut microbiome-derived metabolites such as indole-3-propionate and propionate regulate glial and immune pathways that can alter APP/Aβ pathology in vivo.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test whether candidate regulators causally increase APP catabolic processing.
Description
GO:1902993, positive regulation of amyloid precursor protein catabolic process, is a biological process ontology term that captures any molecular event which increases the frequency, rate, or extent of APP breakdown. APP is a single-pass transmembrane protein whose proteolytic processing is central to Alzheimer's disease (AD) pathogenesis, because sequential cleavage by β-secretase and γ-secretase liberates amyloid-β peptides that aggregate in the brain. Consequently, understanding what positively regulates APP catabolism is fundamental to both basic neurobiology and therapeutic development. The term is not restricted to a single enzyme or compartment; it integrates secretase activities, trafficking, immune modulation, and metabolic signals that converge on APP. For researchers, GO:1902993 provides a standardized annotation framework to compare genetic, pharmacological, and environmental perturbations that alter APP turnover. Because APP catabolism sits at the intersection of neurodegeneration, innate immunity, and gut-brain signaling, it is a high-value target for CRISPR-based functional genomics.
positive regulation of amyloid precursor protein catabolic process At A Glance
| GO ID | GO:1902993 |
|---|---|
| GO term | positive regulation of amyloid precursor protein catabolic process |
| Ontology | biological_process |
| Synonym | activation of APP catabolic process; positive regulation of APP catabolism; upregulation of amyloid precursor protein degradation |
| Major function | Increases the rate or extent of APP proteolytic processing and clearance |
| Related processes | APP catabolic process; amyloid-beta formation; gamma-secretase complex assembly; alpha-secretase activity |
| Cellular context | Endoplasmic reticulum, Golgi, endosomes, lysosomes, and plasma membrane |
| Disease relevance | Alzheimer's disease and other amyloid-related neurodegenerations |
| Research tools | CRISPR KO/KI, secretase inhibitors, APP-GFP reporters, Ribo-seq, proteomics |
What Is GO:1902993?
In our own words, GO:1902993 refers to any biological process that activates or increases the frequency, rate, or extent of the catabolic process of amyloid precursor protein (APP). This includes enhanced proteolytic cleavage of APP by secretases, increased trafficking of APP to degradative compartments, and any upstream signaling event that ultimately accelerates APP breakdown. The term is a positive regulation term, meaning it describes the control point rather than the catabolic process itself.
Why Is positive regulation of amyloid precursor protein catabolic process Important in Cell Biology?
GO:1902993 is important because APP catabolism directly determines the production and clearance of amyloid-β, the peptide that accumulates in Alzheimer's disease brains. Positive regulators of APP catabolism can be either protective or pathogenic depending on which cleavage pathway is enhanced; α-secretase-mediated processing is generally non-amyloidogenic, whereas β- and γ-secretase activities generate Aβ. Thus, annotating genes under GO:1902993 helps distinguish therapeutic targets from risk factors. The term also connects APP biology to innate immunity through IFITM3 and to systemic metabolism through gut microbial metabolites, expanding its relevance beyond classical neuroscience.
• APP catabolism is the upstream source of amyloid-β peptides that aggregate in Alzheimer's disease.
• Positive regulation of APP catabolism can be protective when it favors non-amyloidogenic α-secretase cleavage.
• IFITM3 modulates γ-secretase and links innate immunity to APP catabolic regulation.
• Astrocytic mGluR5-dependent calcium hyperactivity promotes amyloid-β pathology, implicating glial control of APP processing.
• Gut microbial metabolites such as indole-3-propionate and propionate influence cognitive function and amyloidosis in vivo.
• Intestinal epithelial Dicer1 regulates the gut microbiome and Alzheimer's pathology in App-knock-in mice.
• Lipid metabolism, including plasmalogens, intersects with APP processing and AD risk.
• Three-dimensional human neural cell culture models enable mechanistic study of APP catabolism in human-like tissue.
• CRISPR screens can identify novel positive regulators of APP catabolism for therapeutic targeting.
• GO:1902993 provides a standardized annotation for comparing genetic and environmental perturbations of APP turnover.
What Happens During positive regulation of amyloid precursor protein catabolic process?
Initiation of APP proteolysis by secretases
In simple terms: Enzymes cut APP into smaller pieces, and positive regulation means this cutting happens faster or more often.
APP catabolism begins when APP is cleaved by α-, β-, or γ-secretases. Positive regulation of this process increases the frequency or rate of these cleavage events. In human neural cell culture models, APP processing generates amyloid-β peptides that recapitulate AD-like pathology, demonstrating that secretase activity is a key control point. IFITM3 modulates γ-secretase activity, showing that immune proteins can directly enhance or alter APP catabolic flux.
Trafficking and compartmentalization of APP
In simple terms: Where APP goes inside the cell determines which enzymes can cut it.
APP traffics through the endoplasmic reticulum, Golgi, endosomes, and lysosomes, and its localization dictates access to secretases. Positive regulation of APP catabolism can occur through increased endosomal trafficking or altered retention in compartments where β- and γ-secretase are active. Three-dimensional neural culture models have been used to study APP trafficking and processing in a human-relevant context.
Immune and glial modulation of APP catabolism
In simple terms: Brain immune cells and astrocytes can speed up or slow down APP breakdown.
Innate immunity proteins such as IFITM3 modulate γ-secretase and influence APP catabolic processing. Astrocytic mGluR5-dependent calcium hyperactivity promotes amyloid-β pathology and cognitive impairment, indicating that glial signaling can positively regulate APP catabolism toward pathogenic outcomes. Gut microbiome-derived propionate controls reactive astrocytosis during Aβ amyloidosis via IL-17, further linking immune-glial crosstalk to APP processing.
Metabolic and microbiome-derived regulation
In simple terms: Metabolites from gut bacteria and lipids in the body can change how APP is processed.
Gut microbial-derived indole-3-propionate improves cognitive function in Alzheimer's disease, suggesting that microbial metabolites can modulate APP catabolic pathways. Intestinal epithelial Dicer1 regulates the gut microbiome and Alzheimer's pathology in App-knock-in mice, providing genetic evidence that host-microbe interactions influence APP processing. Lipids and plasmalogens also intersect with APP biology and AD risk, indicating that metabolic status contributes to positive regulation of APP catabolism.
Downstream consequences: Aβ generation versus clearance
In simple terms: The end result of faster APP breakdown can be either harmful Aβ peptides or harmless fragments.
Positive regulation of APP catabolism can increase amyloid-β production when β- and γ-secretase activities dominate, or promote non-amyloidogenic processing when α-secretase is favored. In human neural cell culture models, APP processing leads to Aβ accumulation and tau pathology, demonstrating the pathological potential of enhanced APP catabolism. Conversely, shifting the balance toward α-secretase is a therapeutic strategy to reduce Aβ.
Key Genes Involved in GO:1902993 positive regulation of amyloid precursor protein catabolic process
The following genes and proteins are experimentally implicated in APP catabolic processing and its positive regulation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APP | Substrate of catabolic processing; source of amyloid-β peptides | Central to GO:1902993; mutations cause familial AD |
| IFITM3 | Modulates γ-secretase activity and APP catabolic flux | Links innate immunity to APP processing |
| PSEN1 | Catalytic subunit of γ-secretase complex | Mutations cause familial AD; target for γ-secretase modulators |
| PSEN2 | Component of γ-secretase complex | Familial AD risk gene; affects APP cleavage |
| BACE1 | β-secretase; cleaves APP to generate Aβ | Rate-limiting for amyloidogenic APP catabolism |
| ADAM10 | α-secretase; non-amyloidogenic APP cleavage | Protective when upregulated; opposes Aβ generation |
| APOE | Lipid transport; modulates Aβ aggregation and clearance | Major AD risk gene; affects APP catabolism indirectly |
| mGluR5 (GRM5) | Astrocytic calcium signaling; promotes Aβ pathology | Glial regulator of APP catabolic environment |
| IL-17 | Cytokine mediating reactive astrocytosis | Links microbiome to APP pathology |
| Dicer1 | Intestinal epithelial miRNA processing; regulates microbiome | Host gene affecting Alzheimer's pathology in App-KI mice |
| TREM2 | Microglial phagocytosis and immune regulation | Modulates amyloid clearance and APP catabolism |
| CD33 | Microglial inhibitory receptor | AD risk gene; affects amyloid clearance |
| CLU | Chaperone; modulates Aβ aggregation | AD risk gene; interacts with APP processing |
| ABCA7 | Lipid transporter in microglia | AD risk gene; affects APP processing and clearance |
| SORL1 | Endosomal sorting receptor for APP | Controls APP trafficking and catabolism |
| MAPT | Tau protein; downstream of Aβ pathology | Mediates neurodegeneration after APP catabolism |
| GSK3B | Kinase; regulates tau phosphorylation | Downstream effector of APP/Aβ pathology |
How Is positive regulation of amyloid precursor protein catabolic process Regulated?
Positive regulation of APP catabolism is controlled at multiple levels. Transcriptional regulation of secretases (BACE1, ADAM10, PSEN1) alters APP processing capacity. Post-translational modifications and trafficking signals determine APP localization to secretase-rich compartments. Innate immune signaling through IFITM3 directly modulates γ-secretase activity. Glial calcium signaling via mGluR5 promotes amyloid-β pathology, indicating activity-dependent regulation. Gut microbiome-derived metabolites such as indole-3-propionate and propionate regulate immune and glial pathways that influence APP catabolism. Intestinal epithelial Dicer1 and host-microbe interactions further modulate APP pathology in vivo. Lipid metabolism, including plasmalogens, also intersects with APP processing.
positive regulation of amyloid precursor protein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Alzheimer's disease; amyloid-β production | APP knock-in mice; human iPSC-derived neurons |
| PSEN1 | Familial Alzheimer's disease; γ-secretase dysfunction | PSEN1 KO/KI cell lines; 3D neural cultures |
| IFITM3 | Innate immunity modulation of γ-secretase | IFITM3 KO and overexpression in neural cells |
| GRM5 | Astrocytic calcium hyperactivity; Aβ pathology | mGluR5 KO mice; astrocyte-specific manipulation |
| Dicer1 | Gut microbiome regulation; Alzheimer's pathology | Intestinal epithelial Dicer1 KO in App-KI mice |
Alzheimer's disease
Alzheimer's disease is the primary disease context for GO:1902993. Enhanced APP catabolism via β- and γ-secretase generates amyloid-β peptides that aggregate and drive pathology. Human neural cell culture models recapitulate Aβ and tau pathology, confirming the causal link between APP processing and AD. IFITM3 modulation of γ-secretase further ties innate immunity to AD risk. Astrocytic mGluR5 hyperactivity promotes Aβ pathology and cognitive impairment, highlighting glial contributions.
Gut-brain axis and metabolic dysfunction
Gut microbial metabolites influence APP catabolism and AD pathology. Indole-3-propionate improves cognitive function in AD models, while propionate controls reactive astrocytosis during Aβ amyloidosis via IL-17. Intestinal epithelial Dicer1 regulates the microbiome and Alzheimer's pathology in App-knock-in mice. These findings position GO:1902993 within a broader metabolic and immune network relevant to AD.
Lipid metabolism and neurodegeneration
Lipids and plasmalogens are linked to cognition and AD risk. APOE, ABCA7, and CLU are lipid-related AD risk genes that modulate APP processing and Aβ clearance. Dysregulated lipid metabolism may therefore alter positive regulation of APP catabolism, contributing to neurodegeneration.
From positive regulation of amyloid precursor protein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase APP catabolism? | CRISPR knockout in human neural cell lines or iPSCs |
| Does a specific mutation alter secretase activity? | Point-mutation knock-in of APP or PSEN1 |
| Does a risk variant affect APP processing? | Knock-in of AD-associated variants in APP or APOE |
| Where does a regulator localize relative to APP? | Tagged knock-in with fluorescent or epitope tags |
| Does overexpression of a secretase enhance APP catabolism? | Overexpression of BACE1, ADAM10, or PSEN1 |
| Does microbiome manipulation alter APP pathology? | Germ-free or antibiotic-treated App-KI mice |
How to Study the positive regulation of amyloid precursor protein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on APP catabolism | Identify positive regulators of APP processing |
| Point-mutation knock-in | Effect of specific variants on secretase activity | Model familial AD mutations |
| Tagged knock-in | APP localization and trafficking | Live-cell imaging of APP catabolism |
| Overexpression | Gain-of-function effects on APP cleavage | Test secretase or immune modulators |
| RNA-seq | Transcriptional changes in APP catabolic genes | Pathway analysis after perturbation |
| Proteomics | Protein-level changes in secretase complexes | Identify APP interactors |
| 3D neural culture imaging | Aβ and tau pathology | Human-relevant disease modeling |
| Microbiome manipulation | Gut-brain effects on APP pathology | Germ-free or antibiotic-treated mice |
CRISPR knockout and point-mutation screens
CRISPR knockout and point-mutation approaches enable systematic testing of genes for causal roles in positive regulation of APP catabolism. Knockout of candidate regulators in human neural cells can reveal increased or decreased Aβ production. Point mutations can model familial AD variants in APP or PSEN1 to assess their effects on catabolic flux.
Knock-in and tagged reporters
Knock-in of fluorescent or epitope tags into endogenous APP allows real-time tracking of APP trafficking and cleavage in live cells. Tagged knock-in models are particularly useful for imaging APP localization to secretase-rich compartments and for proteomic analysis of APP interactors.
Overexpression and gain-of-function studies
Overexpression of secretases such as BACE1 or ADAM10 can directly test whether increased enzyme levels enhance APP catabolism. Overexpression of immune modulators like IFITM3 can reveal effects on γ-secretase activity and Aβ generation.
Omics and imaging readouts
RNA-seq, Ribo-seq, and proteomics can quantify changes in APP catabolic gene networks after perturbation. Imaging of Aβ plaques and tau pathology in 3D neural cultures or mouse models provides functional validation of APP catabolic changes.
How CRISPR Can Be Used to Study GO:1902993 positive regulation of amyloid precursor protein catabolic process
Knockout
CRISPR knockout of candidate genes in human neural cells or iPSCs can determine whether they are required for positive regulation of APP catabolism. For example, knocking out IFITM3 or PSEN1 would test their roles in γ-secretase-mediated APP processing. Knockout screens can identify novel regulators of Aβ production.
Point Mutation
Point-mutation knock-in can model familial AD variants in APP, PSEN1, or PSEN2 to assess their effects on APP catabolic rate and Aβ generation. Such models are essential for understanding how specific mutations alter secretase activity and processing preference.
Knock-in
Knock-in of tags or reporter cassettes into endogenous APP allows precise tracking of APP catabolism in live cells. Knock-in of AD risk variants in APOE or ABCA7 can reveal how these genes modulate APP processing in a physiological context.
Overexpression
Overexpression of secretases (BACE1, ADAM10) or immune modulators (IFITM3) can test whether increased levels enhance APP catabolism. Overexpression models are useful for gain-of-function screens and for validating therapeutic targets.
How EDITGENE Supports positive regulation of amyloid precursor protein catabolic process Research
Researchers studying positive regulation of amyloid precursor protein catabolic process-related genes often need to determine whether a candidate gene is causally involved in APP processing or merely correlated with disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of amyloid precursor protein catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| Rock2 Knockout CFSC-8B Cell Line | EDJ-KQ14 | Rat | 25537 | Details Get a Quote |
| ROCK2 Knockout HEK293 Cell Line | EDJ-KQ326 | Human | 9475 | Details Get a Quote |
| LYN Knockout HEK293 Cell Line | EDJ-KQ574 | Human | 4067 | Details Get a Quote |
| EFNA1 Knockout HEK293 Cell Line | EDJ-KQ650 | Human | 1942 | Details Get a Quote |
| AGER Knockout HEK293 Cell Line | EDJ-KQ1094 | Human | 177 | Details Get a Quote |
| EFNA3 Knockout HEK293 Cell Line | EDJ-KQ1202 | Human | 1944 | Details Get a Quote |
| ABCA2 Knockout HEK293 Cell Line | EDJ-KQ2538 | Human | 20 | Details Get a Quote |
| EPHA4 Knockout HEK293 Cell Line | EDJ-KQ3334 | Human | 2043 | Details Get a Quote |
| APP Knockout HEK293 Cell Line | EDC09598 | Human | 351 | Details Get a Quote |
| RANBP9 Knockout HEK293 Cell Line | EDJ-KQ6877 | Human | 10048 | Details Get a Quote |
| PICALM Knockout HEK293 Cell Line | EDJ-KQ14752 | Human | 8301 | Details Get a Quote |
| ROCK2 Knockout HeLa Cell Line | EDJ-KQ17971 | Human | 9475 | Details Get a Quote |
| LYN Knockout HeLa Cell Line | EDJ-KQ18031 | Human | 4067 | Details Get a Quote |
| LYN Knockout A-549 Cell Line | EDJ-KQ18970 | Human | 4067 | Details Get a Quote |
| LYN Knockout HCT 116 Cell Line | EDJ-KQ18971 | Human | 4067 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About positive regulation of amyloid precursor protein catabolic process
What is GO:1902993?
GO:1902993 is the Gene Ontology term for positive regulation of amyloid precursor protein catabolic process, describing any event that increases the rate or extent of APP breakdown.
What genes are involved in positive regulation of amyloid precursor protein catabolic process?
Key genes include APP, PSEN1, PSEN2, BACE1, ADAM10, IFITM3, APOE, GRM5, IL-17, and Dicer1, based on published studies.
How does APP catabolism relate to Alzheimer's disease?
Enhanced APP catabolism via β- and γ-secretase generates amyloid-β peptides that aggregate and drive Alzheimer's pathology.
What is the role of IFITM3 in APP processing?
IFITM3 is an innate immunity protein that modulates γ-secretase activity and influences APP catabolic flux.
Can gut bacteria affect APP catabolism?
Yes, gut microbial metabolites such as indole-3-propionate and propionate can modulate immune and glial pathways that influence APP pathology.
What experimental models are used to study APP catabolism?
Models include 3D human neural cell cultures, APP knock-in mice, and CRISPR-engineered cell lines.
How can CRISPR help study positive regulation of APP catabolism?
CRISPR knockout, knock-in, and overexpression can test whether specific genes causally increase APP processing and Aβ production.
What is the difference between α-secretase and β-secretase in APP processing?
α-secretase cleavage is non-amyloidogenic, while β-secretase cleavage initiates the amyloidogenic pathway leading to Aβ production.
Are there drugs targeting APP catabolism?
γ-secretase modulators and BACE1 inhibitors have been explored, but clinical success has been limited; ongoing research focuses on safer modulation.
What methods measure APP catabolic rate?
Methods include Western blot for APP fragments, ELISA for Aβ, live-cell imaging of tagged APP, and proteomics.
Conclusion
GO:1902993, positive regulation of amyloid precursor protein catabolic process, is a central node in Alzheimer's disease biology because it controls the balance between non-amyloidogenic and amyloidogenic APP processing. The term integrates secretase activity, immune modulation, glial signaling, and gut-brain metabolic cues. CRISPR-based models are indispensable for dissecting which genes causally regulate APP catabolism and for prioritizing therapeutic targets. Continued research using these tools will clarify how to safely modulate APP catabolism to treat or prevent AD.
References
- 1. Li L et al.. 2025. Gut microbial-derived indole-3-propionate improves cognitive function in Alzheimer's disease.. Sci Adv 11(48):eadw8410 PMID: 41313780
- 2. Choi SH et al.. 2014. A three-dimensional human neural cell culture model of Alzheimer's disease.. Nature 515(7526):274-8 PMID: 25307057
- 3. Hur JY et al.. 2020. The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer's disease.. Nature 586(7831):735-740 PMID: 32879487
- 4. Yang T et al.. 2026. Astrocytic mGluR5-dependent calcium hyperactivity promotes amyloid-β pathology and cognitive impairment.. Brain 149(1):134-149 PMID: 40377015
- 5. Morley JE et al.. 2010. Lipids and cognition.. J Alzheimers Dis 20(3):737-47 PMID: 20413879
- 6. Chandra S et al.. 2025. The gut microbiome controls reactive astrocytosis during Aβ amyloidosis via propionate-mediated regulation of IL-17.. J Clin Invest 135(13) PMID: 40359034
- 7. Su XQ et al.. 2019. Plasmalogens and Alzheimer's disease: a review.. Lipids Health Dis 18(1):100 PMID: 30992016
- 8. Hao W et al.. 2025. Intestinal epithelial Dicer1 regulates gut microbiome and Alzheimer's pathology in App-knock-in mice.. Alzheimers Res Ther 17(1):202 PMID: 40926280
